| | |
|---|---|
| **Reference:** | FOI.21540.26 |
| **Subject:** | Severe Asthma Biologic Medicines |
| **Date of Request:** | 7 September 2026 |

**Requested:**

Please provide information regarding the use of the following biologic medicines by your organisation:

- Mepolizumab (Nucala)
- Benralizumab (Fasenra)
- Reslizumab (Cinqaero)
- Tezepelumab (Tezspire)
- Omalizumab (Xolair)

1. For each medicine, please provide, by calendar month for the period of the last 12 months:
   a. Number of unique patients receiving the medicine for the treatment of severe asthma
   b. Number of patients newly initiated onto the medicine for severe asthma

Where your organisation cannot distinguish severe asthma from other indications, please provide the corresponding total usage figures and indicate that the data include other indications.

**Response:**

Hywel Dda University Health Board (UHB) is unable to provide you with the exact number of patients due to the low number (less than 5) and have therefore, replaced some of the figures within the tables overleaf with an asterisk (*), as there is a potential risk of identifying individuals if this was disclosed. The UHB is therefore withholding this detail under Section 40(2) of the Freedom of Information Act 2000 (FoIA). This information is protected by the Data Protection Act 2018 (DPA)/UK General Data Protection Regulations (UK GDPR) as its disclosure would constitute unfair and unlawful processing and would be contrary to the principles and articles of the UK GDPR. This exemption is absolute and therefore, there is no requirement to apply the public interest test.

In reaching this decision, the DPA and UK GDPR define personal data as data that relates to a living individual who can be identified solely from that data or from that data and other information, which is in the possession of the data controller.

1a. The UHB provides within the table below, the number of patients receiving the listed medications for the treatment of severe asthma, by month, during the period 1 September 2025 to 31 August 2026.

| Month | Mepolizumab (Nucala) | Benralizumab (Fasenra) | Reslizumab (Cinqaero) | Tezepelumab (Tezspire) | Omalizumab (Xolair) |
|---|---|---|---|---|---|
| September 2025 | 7 | 30 | 0 | 54 | * |
| October 2025 | 14 | 33 | 0 | 56 | * |
| November 2025 | 15 | 22 | 0 | 43 | * |
| December 2025 | 5 | 19 | 0 | 58 | * |
| January 2026 | 13 | 35 | 0 | 72 | * |
| February 2026 | 14 | 38 | 0 | 56 | * |
| March 2026 | 7 | 28 | 0 | 69 | 0 |
| April 2026 | 12 | 32 | 0 | 71 | 0 |
| May 2026 | 11 | 12 | 0 | 66 | 0 |
| June 2026 | 7 | 45 | 0 | 86 | 0 |

| | | | | | |
|---|---|---|---|---|---|
| July 2026 | 16 | 49 | 0 | 87 | 0 |
| August 2026 | 7 | 27 | 0 | 74 | 0 |

1b. The UHB provides within the table below, the number of patients newly initiated onto the listed medications for the treatment of severe asthma, by month, during the period 1 September 2025 to 31 August 2026.

| Month | Mepolizumab (Nucala) | Benralizumab (Fasenra) | Reslizumab (Cinqaero) | Tezepelumab (Tezspire) | Omalizumab (Xolair) |
|---|---|---|---|---|---|
| September 2025 | 0 | 0 | 0 | * | * |
| October 2025 | * | * | 0 | 9 | 0 |
| November 2025 | * | * | 0 | 9 | 0 |
| December 2025 | * | * | 0 | * | 0 |
| January 2026 | * | * | 0 | 6 | 0 |
| February 2026 | 6 | 6 | 0 | 12 | 0 |
| March 2026 | * | * | 0 | 7 | 0 |
| April 2026 | * | * | 0 | 9 | 0 |
| May 2026 | * | * | 0 | 9 | 0 |
| June 2026 | 7 | 7 | 0 | 6 | 0 |
| July 2026 | * | * | 0 | 5 | 0 |
| August 2026 | 0 | 0 | 0 | * | 0 |